XELOX与mFOLFOX6在结直肠癌辅助化疗中依从性的比较

Comparison of compliance of XELOX regimen and mFOLFOX6 regimen in the treatment of colorectal cancer with adjuvant chemotherapy

目的比较卡培他滨联合奥沙利铂(XELOX)方案与亚叶酸钙、5-氟尿嘧啶(5-FU)联合奥沙利铂(mFOLFOX6)方案在结直肠癌辅助化疗中的依从性。方法将124例根治性切除术后的Ⅱ、Ⅲ期结直肠癌患者随机分为两组,XELOX方案组(n=62):卡培他滨(capecitabine,Xeloda)1000mg/m2,2次/d,口服,第1天至第14d;奥沙利铂(oxaliplatin)130mg/m2,静脉滴注,持续3h,第1d;21d为1周期。mFOLFOX6方案组(n=62):亚叶酸钙(CF)200mg/m2,静脉滴注,第1d,5-FU前;5-FU 400mg/m2,静脉推注,第1d,2400mg/m2,静脉持续滴注46h;奥沙利铂85mg/m2,静脉滴注,持续3h,第1d;14d为1周期。比较两组按时化疗的患者、调整剂量患者和完成全部疗程的患者有无差异。结果 XELOX组和m FOLFOX组按时化疗率分别为82%和77%,差异无统计学意义;需要调整剂量的发生率分别为24%和13%,差异有统计学意义;完成足疗程率分别为92%和89%,差异无统计学意义。结论与mFOLFOX6方案相比,XELOX方案有较多患者需要调整奥沙利铂的剂量。

Objective To compare the compliance of capecitabine, oxaliplatin （XELOX） and 5 - fluorouracil （ 5 - FU）, leucovorin（ LV）, oxaliplatin （mFOLFOX6） in treatment of eoloreetal cancer with adjuvant chemotherapy. Methods Totally 124 patients with II and III stage colorectal cancer were enrolled into this study, 62 patients were randomly divided into XELOX group and mFOLFOX6 group respectively. In XELOX group, patients were treated with eapeeitabine 1000mg/m^2 oral twice every day from day 1 to day 14 ; oxaliplatin 130mg/m^2 iv infusion for 3 hours on day 1, repeated every 3 weeks. In mFOLFOX6 group, CF 200mg/m^2 iv in fusion dl followed by 5 - FU 400mg/m^2 iv bolus on day 1 and 2400mg/m^2 iv infusion continuously for 46 hours; oxaliplatin 85mg/m^2 iv infusion for 3 hours on day 1, repeated every 2 weeks. To compare the difference between the two groups in the number of patient with chemotherapy on time, the number of patient with adjusted dose and the number of patient who completed the whole course of treatment. Results The number of chemotherapy on time in XELOX group and mFOLFOX group were 82% and 77% respectively, there was not statistically difference. The incidence rate of adjusting the dosage was 24% and 13% , the difference was statistically significant. Complete the full course rate were 92% and 89%, there was no statistically difference. Conclusion Compared with mFOLFOX6 regimen, in XELOX scheme more patients need to adjust the dose of oxaliplatin.